Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 7, 2014, Pages 1916-1919

  Hernández Novoa, Beatriz ^a   Madrid Elena, Nadia ^a   Dronda, Fernando ^a   Pérez Elias, María J ^a   Casado, José L ^a   Pérez Molina, José A ^a   Moreno, Ana ^a   Estébanez, Miriam ^b   González, Juan ^b   Zamora, Javier ^a   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Clinical trials; Dual mixed tropic; R5 tropic

Indexed keywords

MARAVIROC; TROFILE; UNCLASSIFIED DRUG; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MONOTHERAPY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PREDICTION; SHORT COURSE THERAPY; VIRAL PHENOMENA AND FUNCTIONS; VIRAL TROPISM; VIROLOGICAL RESPONSE; VIRUS LOAD; CLINICAL TRIAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD; VIRAL TROPISM; YOUNG ADULT;

EID: 84902489630     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku059     Document Type: Article

References (15)

1. Vandekerckhove LP, Wensing AM, Kaiser R et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11: 394-407.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. http://aidsinfo. nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (13 September 2013, date last accessed).
3. Fatkenheuer G, Pozniak AL, Johnson MA et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11: 1170-2.
4. Fatkenheuer G, Nelson M, Lazzarin A et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442-55.
5. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
6. Westby M, LewisM, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80: 4909-20.
7. Moyle GJ, Wildfire A, Mandalia S et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191: 866-72.
8. TM HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 2009; 3: 94-102.
9. Genebat M, Ruiz-Mateos E, Leon JA et al. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J Antimicrob Chemother 2009; 64: 845-9.
10. Connor RI, Sheridan KE, Ceradini D et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185: 621-8.
11. Wilkin TJ, Su Z, Kuritzkes DR et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44: 591-5.
12. Archer J, Weber J, Henry K et al. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One 2012; 7: e49602.
13. Obermeier M, Symons J, Wensing AM. HIV population genotypic tropism testing and its clinical significance. Curr Opin HIV AIDS 2012; 7: 470-7.
14. Swenson LC, Daumer M, Paredes R. Next-generation sequencing to assess HIV tropism. Curr Opin HIV AIDS 2012; 7: 478-85.
15. Swenson LC, Mo T, Dong WW et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011; 203: 237-45.